VentriPoint Diagnostics Ltd (VPTDF)

[teq0904]

Dear Friend;

Attached is news we released today. her is some background.

1. Cancer is a big application with 23M people in USA with cancer and 1.7M new patients a year. Since all chemotherapy agents hurt the heart, the American Heart Association (AHA) has put out a statement saying cancer patients should ask to have their heart examined before, during and after therapy as they are more likely to die from heart problems than cancer after they have the therapy.
2. MD Anderson has been ranked as the number one cancer hospital in the USA 28 out of the last 30 years and is clearly the leader in clinical innovation, so we are very pleased they have ordered the VMS+ and will immediately start using it clinically - no research study as they know heart problems are prevalent.
3. MD Anderson is not just a hopsital but a network of several hospitals who see 1.5M patients per year and perform almost 600,000 imaging studies. This network would need 750 VMS+ devices to treat their patients according to the AHA guidelines (3 scans per patient) at full utilization. Many survey’s have shown ultrasound equipment is used only 50% to 60% of the capacity due to scheduling and other issues, so in reality they would need 1,500 machines just for their network. The chief cardiologists will be using the VMS+ initially in the main hospital in Houston to get a good understanding of how it works and how it can be used in all their hospitals.
4. There are 1,500 cancer centres in USA, who deal with the 23M patients. Patients come back twice a year to check to see if the cancer has regrown and the AHA is saying they really should be more worried about heart conditions then cancer. Ask anyone you know who has cancer therapy of they have had an echocardiogram. I am doing this and I have yet to find anyone. To follow the AHA guidelines in the USA with the normal utilization rates would require 20,000 VMS+ machines. At $75,000 each this would be $1.5B of sales. That is just the USA. European market is 1.5 times the USA.
5. Note hypertension (100 million people in USA , 80,000 VMS+ machines needed) is an even bigger application and we are working on a lead order in this space as well.
6. Reducing the use of contrast media which is used in 20-30% or all echocardiograms (40M per year in USA) is another large application which would require 3,000 VMS+ machine to address.

Thank you for your continued support,

George Adams

http://www.stockhouse.com/companies/bullboard/v.vpt/ventripoint-diagnostics-ltd?postid=28126475#KLABfbUvJoZSlbs4.99

[UCParadise]

MD Anderson Cancer Center is the First Hospital in USA to Order the VMS+ Complete Heart Analysis System


http://www.ventripoint.com/md-anderson-orders-vms.html

[UCParadise]

Ventripoint Receives Market Clearance from US-FDA for Complete Heart Analysis System using 2D Ultrasound


https://web.tmxmoney.com/article.php?newsid=5182164249301316&qm_symbol=VPT

[UCParadise]

Health Canada approval caused a 5 fold increase in price from the open to the high. Wait to see what FDA approval will do.

[UCParadise]

Dear Stakeholder; 
 
Attached is the press release about our FDA filing and here is some background.
 
1.  We are our own predicate device which means since we are approved for RV analysis, the FDA compares our current updated device (all 4 chambers) to our existing device (RV only).  Of course the devices are identical since all we have changed is the databases, which are used to determine the volumes and ejection for each chamber of the heart.  
2.  We use the same artificial intelligence approach for all the chambers so the actual workings of the VMS+ device have not changed and so all the previous reviews by the FDA about how the device works and its safety are valid.
3.  This means the FDA has very little to do except look at the mean and the variance for all three measured parameters volume at start of the heart beat, volume at the end of the hearts beat and the ejection fraction for the additional 3 chambers (LA.RA,LV) so  2x3x3 or 18 numbers and these all show equivalency (within +/-10%) to MRI.  We still used the MRI as the reference determination for each hear analyzed.
4.  Previously the FDA has been concerned we do hearts form many different heart conditions (CHD, PAH, congestive heart failure, MI, ischemic heart failure, etc.) so we did all of these and many more so they can have confidence the VMS+ can analyze any heart.
5.  Last time we applied to go from PAH to all hearts for RV analysis it took them 42 days to approve the application, so we are hopeful this one will be equally as quick, but you never know with the FDA.
6.  We know the application is complete as it has passed administrative review and so is actively being reviewed for content.
 
As usual, if you have questions send me an email or call.
 
Thanks for your continue support.

Regards,

George Adams, PhD, ICD.D
CEO
Ventripoint Diagnostics Ltd..
Cell: 519-803-6937
TSXV: VPT

Read more at http://www.stockhouse.com/companies/bullboard#Jf3yudyB49rAtZM0.99

[UCParadise]

http://www.ventripoint.com/vpt-applies-for-fda.html

[UCParadise]

I'm on board..picked em up today

This looks really good

GL

[whatisthecolorofmone]

Dot imaging for life..

http://www.ventripoint.com/press-releases.html

[whatisthecolorofmone]

This will be the stock for 2018

Huge market potential...
Of course, it's extremely early days for this firm but the potential market for such a device is huge. There are 40mln eco-cardiograms performed each year alone in the US, points out Adams.

At $100 a pop, that's $4bn of revenue going into the pot, of which VentriPoint reckons it can get 25%.

That would send the firm, which still has a market cap of only $25mln even after the fundraise, into orbit.

Adams says the group’s valuation is still very low for a company with approved products in a multi-billion dollar market.

Next on the horizon is to develop the device sufficiently to monitor 3D and 4D ultrasound images - something which big firms like Philips, Samsung and Simens have been working on for 15 years, says Adams, without success.

The other big market is cancer, he adds, explaining that the VMS technology would be able to accurately measure the size of a tumor, and whether it had shrunk or not.

"That's becoming very important because even now in the USA , you don’t get paid for doing a procedure any more in cancer, you get paid if you have a positive outcome," he notes.

So there's no doubt VentriPoint is at a critical point and at the start of a potentially extremely exciting journey. It will be a very interesting stock to watch.

[whatisthecolorofmone]

$VPTDF Receives CE Mark for VMS+ Whole Heart Analysis System

https://web.tmxmoney.com/article.php?newsid=5317549590735503&qm_symbol=VPTDF:US …